Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
21.18
-0.24
(
-1.12% )
|
21.15
|
600 |
21.18
|
7,000 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 15.08.2025.
Interest
Strong
Strong
Three stars since 24.02.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 24.02.2026 at a price of 21.43.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 20.02.2026.
4wk Rel Perf
6.20%
6.20%
The four-week dividend-adjusted overperformance versus SP500 is 6.20%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.93%.
Mkt Cap in $bn
3.35
3.35
With a market capitalization between $2 & $8bn, DENALI THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.12
0.12
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-21.45
-21.45
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
2.50%
2.50%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
107
107
For 1% of index variation, the stock varies on average by 1.07%.
Correlation
0.33
0.33
Stock movements are strongly independent of index variations.
Value at Risk
12.21
12.21
The value at risk is estimated at USD 12.21. The risk is therefore 56.98%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.11.2020
27.11.2020